Literature DB >> 3625491

Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat.

R Mehvar, F Jamali.   

Abstract

To investigate the pharmacodynamics of tetrabenazine [1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2-H-benzo(a)quinol izine-2- one; 1], the drug of choice in the control of Huntington's chorea and tardive dyskinesia, and its major metabolite, dihydrotetrabenazine (2), ip doses of 3 mg/kg of the drug and the metabolite were administered to rats. Animals were decapitated at 0.0, 0.5, 2, 5, and 12 h. Brain and serum concentrations of 1 and 2, and brain concentrations of dopamine, norepinephrine, and serotonin were measured. Time courses of 1 and 2 in the brain (site of action) were parallel to those in serum, indicating that the brain is a part of the central compartment for both compounds. Despite its greater polarity, 2 was able to readily cross the blood-brain barrier. The monoamine depletions at any time following the administration of 2 were at least equal to or greater than those observed following the administration of the same dose of 1. After both compounds, the maximum serum and brain concentrations and maximum depletions were observed with the first sample at 0.5 h, with dopamine and serotonin being the most and least affected, respectively. The brain levels of the amines returned to the control values a maximum of 12 h after ip injections of either 1 or 2. Sigmoidal relationships were found between the monoamine levels and the corresponding log brain or serum concentrations of 1 or 2. The concentration-response curves of 2 following the administration of 1 and 2 were superimposable, suggesting that the observed activity after tetrabenazine injection is mainly, if not entirely, due to the formation of the active metabolite.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3625491     DOI: 10.1002/jps.2600760610

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.

Authors:  Samuel Frank
Journal:  BMC Neurol       Date:  2009-12-18       Impact factor: 2.474

Review 3.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  Tourette's syndrome and role of tetrabenazine: review and personal experience.

Authors:  Mauro Porta; Marco Sassi; Mario Cavallazzi; Maurizio Fornari; Arianna Brambilla; Domenico Servello
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 5.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

6.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

Authors:  Samuel Frank
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

7.  Management of Huntington's disease: role of tetrabenazine.

Authors:  Marina de Tommaso; Claudia Serpino; Vittorio Sciruicchio
Journal:  Ther Clin Risk Manag       Date:  2011-03-21       Impact factor: 2.423

Review 8.  Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation.

Authors:  Claudia Rangel-Barajas; George V Rebec
Journal:  J Huntingtons Dis       Date:  2016-12-15

9.  Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine.

Authors:  Heather Skor; Evan B Smith; Gordon Loewen; Christopher F O'Brien; Dimitri E Grigoriadis; Haig Bozigian
Journal:  Drugs R D       Date:  2017-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.